Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.66 |
| ▸ | NPC1 | O15118 | 7/20 | 0.66 |
| ▸ | RAB9A | P51151 | 7/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | TP53 | P04637 | 3/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | STAT1 | P42224 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10112206 | 0.82 | MAPT (0.56) | MAPTSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL2411656 | 0.82 | MEN1 (0.58) | MAPTSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL13860592 | 0.82 | ESRRA (0.53) | MAPTSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL10112053 | 0.82 | SMN1; SMN2 (0.59) | MAPTSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL5306918 | 0.82 | MAPT (0.46) | MAPTSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL14996633 | 0.82 | SMN1; SMN2 (0.51) | MAPTSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL167998 | 0.82 | SMN1; SMN2 (0.56) | MAPTSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL5330573 | 0.81 | MAPT (0.46) | MAPTSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL2685502 | 0.80 | KDR (0.53) | MAPTSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL13974490 | 0.79 | RAB9A (0.65) | MAPTSMN1; SMN2NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312722-B2 | Hsp90 inhibitors and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2021188907-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200354373-A1 | HSP90 INHIBITORS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-11-12 | — | — | US | disclosed |
| WO-2020227368-A1 | HSP90 INHIBITORS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-9981959-B2 | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981959-B2 | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20150166564-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | Array BioPharama Inc. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150166564-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | Array BioPharama Inc. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2014078331-A1 | N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078328-A1 | N-BICYCLIC ARYL,N'-PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078322-A1 | THIAZOLYL AND OXAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078325-A1 | N-(MONOCYCLIC ARYL),N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078408-A1 | BICYCLIC HETEROARYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078454-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2012158413-A2 | PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | NR5A2, NR5A1, GPER1 | MAPT 4520/4885SMN1; SMN2 4595/4885NPC1 706/4885 |
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | TK1, UACA, TDP1 | MAPT 464/4885SMN1; SMN2 2313/4885NPC1 3749/4885 |
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | RET, TK1, DSTYK | MAPT 118/4885SMN1; SMN2 1881/4885NPC1 3424/4885 |
| US-20200354373-A1 | HSP90 INHIBITORS AND USES THEREOF | HSP90AB1, HSP90B1, HSP90AA1 | MAPT 494/4885SMN1; SMN2 4707/4885NPC1 2456/4885 |
| US-20150166564-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | RET, TK1, DSTYK | MAPT 118/4885SMN1; SMN2 1881/4885NPC1 3424/4885 |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | MAPT 464/4885SMN1; SMN2 2313/4885NPC1 3749/4885 |
| US-11312722-B2 | Hsp90 inhibitors and uses thereof | HSP90AB1, HSP90B1, HSP90AA1 | MAPT 494/4885SMN1; SMN2 4707/4885NPC1 2456/4885 |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | MAPT 464/4885SMN1; SMN2 2313/4885NPC1 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.